Sanofi Ends Development of Two Phase III Drugs - - BioPharm International

ADVERTISEMENT

Sanofi Ends Development of Two Phase III Drugs


Sanofi has discontinued development of two investigational drugs in Phase III development, iniparib, a drug to treat non-small cell lung cancer, and otamixaban, an anticoagulant, based on recent clinical results. Sanofi will take an after-tax change of $285 million for iniparib.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines

Click here